CD34 and HIV infectious disease: The most common method involves two steps: modifying the cells (CD4+ T cells and CD34+ hematopoietic stem/progenitor cells) in vitro and then reinfusing the modified cells into patients.268,269 Several clinical trials involving CD4+ T cell modification in the context of HIV infection have already been tested.